← back to picks

Reporting EUR Credit Aaa/AAA Valuation 2026-05-24 Damodaran FCFF · 1000-iter MC Council-revised Damodaran FCFF · Dark

Sub-scale vet-pharma compounder, market discount to post-governance intrinsic +12.6% MoS

Market sits in MC lower quartile

Post-15% governance intrinsic lands at €405.27 against a €360 Euronext print, with Monte Carlo pricing only 13.3% of paths below market. Thin but real margin on a Dick-family vehicle the council priced as an asset class, not a haircut.

            MC fan p5–p95 (EUR/share); market
            €360 sits inside the p5–p25 tail →
            only 13.3% of iterations have
            intrinsic < market.
          

Sector Animal-health pharma · #6 global Geo Europe-led · FR 16% / US 12.5% / IN 7% MC σ ±€37.63 · p5 €343 / p95 €471 Governance Family-controlled · Dick 50.09% / 66.20% vote Quality 100% Buy · FY25 organic +7.9% CERS Council Council-revised · margin 17% / gov 15%

Intrinsic / share

€405.27

post 15% gov

Market / share

€360.00

Euronext Paris

Margin of safety

+11.2%

vs intrinsic

Enterprise value

€4.17B

74.6% terminal

Cost of equity / debt

7.81% / 2.09%

β 0.98 · CRP 1.28%

Terminal ROIC / g

14.10% / 2.30%

spread ~679bp

What it sells, where it sells

Operating segments

Companion animalsPet meds, vaccines, dermatology, dental, petfood · Q1'26 +9.9% CERS 60.7%

Farm animalsCattle, swine, poultry, aquaculture · Q1'26 +8.4% CERS 39.3%

Supercharge platformsCross-cutting specialty: mobility, dental, ear, endocrinology, reproduction · ~+15% CERS cross

Country mix (revenue-weighted CRP input)

🇫🇷France16.0%

🇺🇸United States12.5%

🇮🇳India7.0%

🇬🇧United Kingdom6.0%

🇧🇷Brazil6.0%

🇯🇵Japan5.5%

🇮🇹Italy5.0%

🇪🇸Spain5.0%

🇩🇪Germany5.0%

🇨🇱Chile5.0%

🌐Other (12 countries)22.0%

Top 10 countries = 78% of FY25 revenue; tail bundles Australia 5.0%, Netherlands 4.6%, Mexico 4.2%, South Africa 3.5%, China 3.0%, NZ 1.9%, Türkiye 1.7%, Thailand 1.5%, Canada 1.1%, Taiwan 0.5%. Middle East directly-at-risk exposure (Iran, Iraq, Lebanon, Syria, Yemen, Israel) is <0.5% combined per Virbac IR.

Quality profile & the two-sided argument

A five-axis read on the DCF's load-bearing assumptions, plus the bull-vs-bear case distilled into anchor bullets.

Quality snowflake (each axis 0–6)

Growth durability4/610y organic CAGR ~6%; Q1'26 +7.7% CERS; FY26 guide 5.5-7.5%; bolt-on M&A adds ~1pt/yr.

Margin trajectory3/6FY25 adj EBIT 16.3% (full 15.4%); mgmt 2030 ambition 20%; council Y10 base 17%.

Capital efficiency2/6ROIC compressed 19% (3y avg) → 10-12% TTM; recovery hinges on FY27-28 capex normalisation.

Balance sheet6/6Net debt €173M, 1.0x ND/EBITDA, AAA synthetic rating; ample headroom for further bolt-ons.

Governance2/6Dick family 50% econ / 66% voting; 2/7 independent board; Sentinel precedent — 15% haircut.

The two-sided case

Bull case

Operationally pristine Q1 2026. +7.7% CERS, companion +9.9% / farm +8.4%, Supercharge specialty platforms +15%.
N. America surge. +20.7% CERS in Q1, ahead of any FY-guidance raise — read by Stifel as 12%+ 2026 EPS growth.
Programmatic M&A flywheel. Sasaeah + Globion + Mopsan + Thyronorm (£100M, Dec 2025, accretive Y1) inside 18 months.
€500M+ dry powder at 1.0x ND/EBITDA. Balance sheet underleveraged for a Drugs (Pharma) compounder; bolt-on cadence can sustain ~1pt/yr inorganic.
100% Buy analyst coverage. Stifel €440, BNP Exane €440, Kepler €415 — average target €413-420 vs €360 today (+13-19%).
Management 2030 ambition: 20% adjusted EBIT. +3.7pt build off FY25 16.3% with manufacturing-transformation capex normalizing.

Bear case

Sub-scale #6 vs four giants. Zoetis/Boehringer/Merck/Elanco are 3-5x larger; no sub-scale animal health peer has cracked 18% EBIT sustainably (council).
ROIC compressed 19% → 10-12% TTM. Recovery is the unproven core of the thesis — capex still ramping (€102M FY25 → €125M FY26 guide) through FY28.
AMR regulatory overhang. Farm segment ~40% of revenue sells WHO Critically Important Antimicrobials (Tulissin, Promote®) without explicit responsible-marketing policy.
Dick family 50/66 economic/voting permanent. ISS 2026 policy flags unequal voting. 2/7 independent directors; minority position is uncontestable.
Sentinel destroyed $410M (2015→2020) by the same family still in control. Capital allocation discipline is improving but not proven.
FX drag compressing reported growth. Q1 2026 +2.2% at actual rates vs +7.7% CERS; 55%+ of revenue non-EUR with strong euro overhang.

Thesis & open questions

Investment thesis

Quality compounder, discount cosmetic. Operationally pristine Q1 2026 (+7.7% CERS) at €360 vs €405 intrinsic = +12.6% MoS after 15% governance discount.
Programmatic M&A flywheel funded and proven. Sasaeah, Globion, Mopsan and £100M Thyronorm closed inside 18 months; €500M+ dry powder at 1.0x ND/EBITDA.
Margin glide path credible but capped. Management's 2030 ambition is 20% adjusted EBIT; council haircut to 17% full EBIT — no sub-scale peer has cracked 18%.
ROIC compression is investment-cycle drag, not value destruction. R&D ~8% of revenue and €125M FY26 capex guide normalize post-FY28; ROIC reverts to 15-17%.
Governance overhang priced via 15% discount. Dick family 50/66 econ/voting permanent; €71/share haircut from €476.79 pre-governance intrinsic to €405.
MC: P(intrinsic < market €360) = 13.3%. 87% confidence price sits below fair after stressing margin band to 15% downside and governance to 20%.

Key debates (where the model can fail)

Q: Can a sub-scale #6 player actually clear 18% EBIT by 2030?

A: Probably not the 20% mgmt ambition; 17% is the honest center. No sub-scale animal-health peer (Elanco, Dechra at $1.5-2B revenue) has held 18%+ sustainably — only Zoetis at 3-5x the scale. Base case 17% full EBIT, MC tail to 19% bull / 15% bear.

Q: Is the ROIC collapse (19% → 10-12% TTM) investment cycle or structural?

A: Cycle if FY28 normalizes; dead-money risk if it doesn't. R&D 8%, capex €102M FY25 → €125M FY26 + Sasaeah/Globion/Mopsan/Thyronorm integration ramping. Recovery thesis credible to 15-17% FY29-30. Outsider's warning: "11% ROIC forever" = dead-money five years, not a crash.

Q: 10% governance discount — placeholder or principled?

A: Moved to 15%; sits at council median. Dick family 50.09% economic / 66.20% voting via French double-voting permanent and uncontestable. Contrarian floor 15-20%; Expansionist Hermès-premium argument was flagged as weakest by 4 of 5 peer reviewers. 15% splits Sentinel-style capital-allocation risk (~7-10%) and optionality/liquidity loss (~5-8%).

Q: AMR regulation on the 40% farm book — modeled or not?

A: Not modeled as a discrete scenario; sits in the MC left tail via the terminal_growth clip. Tulissin/tulathromycin exposure real; EU veterinary antibiotic restrictions tightening. Contrarian recommends: 15% probability of structural farm reset → revenue -15%, margin -300bps within 5 years. Re-run explicitly before sizing.

Q: Q1 2026 +7.7% CERS and mgmt held guidance — sandbagging or warning?

A: Unresolved — the tell prints September 17 with Q2. N. America +20.7% CERS, companion +9.9%, farm +8.4%, Supercharge +15% — and they didn't raise. Outsider read: mgmt sees something in Q2-Q4. Executor's Monday action: read the Q1 transcript Q&A verbatim.

Assumptions & provenance

Every input shown against its industry benchmark with a one-line rationale. This is what the DCF is actually built on.

Input	Our value	Benchmark	Δ	Rationale
Y1-5 revenue growth	6.5%	5.5-7.5% FY26 mgmt guide	at mid-guide	Mid-guide organic + ~1pt Thyronorm + ~1pt M&A; 10y CAGR `~6%`, Q1 2026 `+7.7%` CERS confirms.
Year-10 op margin	17%	20% mgmt 2030 adj EBIT ambition	−300 bp	Post-council haircut from 18% → 17%; no sub-scale ($1.5-2B) animal-health peer sustains 18%+ EBIT.
Terminal growth	2.3%	2.4% EUR risk-free ceiling	−10 bp	One notch below the EUR ceiling; secular animal-health tailwind already absorbed in the base path.
Sales-to-capital Y6-10	1.20	1.07-1.11 Drugs (Pharm) global/US	+9-13%	Capex moderates post-FY28 industrial-transformation cycle; M&A integration complete, operating leverage kicks in.
Sales-to-capital Y1-5	1.00	1.07-1.11 Drugs (Pharm) global/US	−7-11%	Heavy capex (€125M FY26 guide) + Sasaeah/Globion/Thyronorm integration capital ramping through FY28.
WACC (terminal)	~7.3%	EUR rf 2.4% + ERP 4.23% + blended CRP 1.28%	auto-resolved	Engine derives from 20-country revenue weights + Damodaran 2026 CRPs; no firm-specific override.
Levered β	~0.98	~1.00 Drugs (Pharm) unlevered cohort	industry	Industry unlevered β ≈ 1.0, lightly relevered for `~1.0x` ND/EBITDA.
Effective tax rate	30.9%	25.5% France federal+social marginal	+540 bp	Strict IFRS FY25 (`67.2/217.5`); elevated by Chile/Mexico/IMEA mix vs French statutory.
R&D capitalization	ON · 10y	10y Drugs (Pharm) default life	at default	R&D `~8%` of revenue (€116M FY25); 6-year history loaded for asset-base build.
Governance discount	15%	10% initial pre-council	+500 bp	Raised post-LLM-council: Dick family 50/66% voting + Sentinel precedent + 2/7 independent board.

Where the value could land

Bull / Base / Bear scenarios overlaid with the Monte Carlo distribution. Each band shows the PT range, with a tick marking the central PT.

Bear

€343–€378

–5% to +5%

Y10 op margin holds at 15–16% (sub-scale peers can't crack 18%), M&A pace slips and FX drag on the ~55% non-EUR book persists; spans MC p5 to the Executor 16%-margin sensitivity case.

P ≈ 25%

Base

€405

+12.5%

Council-revised inputs hold: Y10 op margin 17%, 6.5% blended growth, governance discount 15%. MC mean €403, p50 €402, sits inside the €407–€440 sell-side consensus band.

P ≈ 50%

Bull

€440–€471

+22% to +31%

Mgmt 2030 ambition delivers (Y10 adj EBIT ~19–20%), programmatic M&A flywheel continues at +1.5pt/yr, governance discount compresses to 5–10%; aligns with Stifel/BNP Exane €440 targets and MC p95 €471.

P ≈ 25%

Risks to thesis (tail, not bear case)

Y10 margin overrunHigh

R&D running ~8% of sales with €125M capex guided for FY26. If the investment cycle slips past FY28, EBIT stays at 15-16% and the 17% Y10 base case fails — the council's load-bearing concern.

Dick family governance overhangHigh

Family holds 50.09% economic / 66.20% voting; ISS 2026 flags the unequal voting structure. €71/share equity haircut already applied via a 15% discount — Contrarian argued a 20% floor is more defensible.

AMR regulatory tail on farmMed

Farm animals are ~40% of revenue and the portfolio includes WHO critically important antimicrobials (Tulissin). Not in the base MC; a structural AMR reset inside 5 years would force -15% revenue and -300bps margin.

Pacific competitive pressureMed

Australia posted a double-digit Q1 2026 decline in vaccines and parasiticides. Continued share loss to Zoetis and Boehringer compresses growth in the ~5% of revenue tied to the Pacific region.

FX translation dragMed

Euro strength compressed Q1 2026 reported growth to +2.2% vs +7.7% at constant FX. With ~50-60% of revenue non-Eurozone, the FY25 EBIT base used to anchor margins may be FX-flattered.

Capital-allocation precedentMed

Sentinel was a $410M 2015 buy written down by 2020 — a strategic miss. Recent programmatic M&A (Sasaeah, Globion, Thyronorm) looks disciplined, but ~€500M of dry powder leaves room for a new mistake.

10-year forecast

Revenue €1.56B → €2.75B over 10y; R&D-adjusted operating margin starts ~20% (R&D capitalised) and decays to 17.00% by Y10.

Monte Carlo distribution

1000 iterations randomising revenue growth, Y10 op margin, terminal growth and governance discount. P(intrinsic < market €360.00) = 13.3%.

Mean €403.10 ± €37.63; p5 €343 · p25 €378 · p50 €402 · p75 €428 · p95 €471.

Cost of capital build

Risk-free rate	2.40%
Mature-market ERP	4.23%
Levered β	0.98
Weighted CRP	1.28%
Cost of equity	7.81%
Pre-tax cost of debt (synth Aaa/AAA)	2.09%
D / V	~8%
WACC	7.30%

Full year-by-year DCF

Year	Revenue	Op mgn	EBIT	EBIT(1−t)	Reinvest	FCFF	PV
1	€1.56B	20.22%	€316M	€218M	€95M	€123M	€114M
2	€1.66B	19.86%	€330M	€228M	€101M	€127M	€110M
3	€1.77B	19.51%	€345M	€239M	€108M	€131M	€106M
4	€1.88B	19.15%	€361M	€249M	€115M	€134M	€101M
5	€2.01B	18.79%	€377M	€261M	€123M	€138M	€97M
6	€2.14B	18.43%	€394M	€277M	€109M	€168M	€110M
7	€2.28B	18.07%	€411M	€293M	€116M	€177M	€108M
8	€2.42B	17.72%	€430M	€311M	€123M	€187M	€107M
9	€2.58B	17.36%	€448M	€329M	€131M	€198M	€105M
10	€2.75B	17.00%	€468M	€348M	€140M	€208M	€103M

Methodology & flags

Damodaran FCFF DCF, 10y explicit + perpetuity. R&D capitalised (10y life, €416M asset value, +€75.5M adj. EBIT delta); IFRS-16 leases in book debt (no separate cap). Synth credit Aaa/AAA. CRP from revenue-weighted 20-country mix × Damodaran 2026 CRPs. Monte Carlo: 1000 iterations across 4 axes (revenue growth, Y10 margin, terminal growth, governance discount). Engine v1.0.0 · result: valuations/virp/output/2026-05-24-result.json

R&D cap: ON · Lease cap: OFF · Failure: OFF · ESO: OFF
Governance haircut: 15% (€476.79 > €405.27)
Sensitivity tornado: not run (MC supersedes)

Damodaran FCFF DCF · dark theme. Generated 2026-05-24T18:12:03 from valuations/virp/output/2026-05-24-result.json.